Atherosclerosis (AS) is a complex vascular disease that seriously harms the health of the elderly. It is closely related to endothelial cell aging, but the role of senescent cells in atherogenesis remains unclear. Studies have shown that peroxisome proliferator-activated receptor alpha (PPARα) inhibits the development of AS by regulating lipid metabolism. Our previous research showed that PPARα was involved in regulating the repair of damaged vascular endothelial cells. Using molecular biology and cell biology approaches to detect senescent cells in atherosclerosis-prone apolipoprotein E-deficient (Apoe−/−) mice, we found that PPARα delayed atherosclerotic plaque formation by inhibiting vascular endothelial cell senescence, which was achieved by regulating the expression of growth differentiation factor 11 (GDF11). GDF11 levels declined with age in several organs including the myocardium, bone, central nervous system, liver, and spleen in mice and participated in the regulation of aging. Our results showed that PPARα inhibited vascular endothelial cell senescence and apoptosis and promoted vascular endothelial cell proliferation and angiogenesis by increasing GDF11 production. Taken together, these results demonstrated that PPARα inhibited vascular endothelial cell aging by promoting the expression of the aging-related protein GDF11, thereby delaying the occurrence of AS.

1. Introduction

The occurrence and development of atherosclerosis (AS) are closely related to endothelial dysfunction caused by endothelial cell aging. Many cardiovascular risk factors, such as hypertension, hyperlipidemia, and diabetes, can cause endothelial cell aging, leading to endothelial cell dysfunction and AS [1, 2]. Vascular endothelial cells are a semipermeable membrane barrier between the blood and subendothelial tissues which have sensing and secretion functions, and they produce effector molecules to regulate thrombosis, inflammation, vascular tone, and vascular reconstruction [3]. Aging impairs the function of endothelial cells, increases their permeability to lipoproteins and plasma components, reduces nitric oxide secretion, and increases intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) secretion and nuclear transcription factor-xB (NF-xB) expression, favoring a proinflammatory and proapoptotic state [4–6]. Studies have shown that telomere length of endothelial cells decreases with age, and the degree of shortening is more pronounced in sites prone to AS [7]. Animal experiments have found that vascular branches or branch points were susceptible to hemodynamic shearing and stretching changes, resulting in chronic damage to endothelial cells, and endothelial cells at these sites improve cell turnover to maintain their own morphology and function and are prone to senescence, which may cause atherosclerotic plaque formation [8]. Platelet-derived growth factor (PDGF) secreted by damaged endothelial cells promotes smooth muscle cell chemotaxis and proliferation. Inflammatory factors released by damaged endothelial cells recruit a large number of monocytes and polymorphonuclear neutrophils. ICAM-1 and VCAM-1 secreted by damaged endothelial cells promote adhesion of monocytes. Therefore, endothelial dysfunction caused by endothelial cell aging is likely the initiating factor of AS [9].

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that regulates the transcription of various target genes by binding to ligands (such as fatty acids and fibrates), thereby affecting lipid metabolism,
inflammatory response, and AS; PPARα also plays a role in maintaining blood sugar stability and enhancing tissue sensitivity to insulin [10]. In addition, PPARα not only prevents the development of AS but also stabilizes atherosclerotic plaques. Moreover, it even reverses the development of atherosclerotic plaques and prevents the occurrence of acute cardiovascular events. Studies have shown that PPARα directly inhibits the accumulation of monocytes to vascular endothelial cells and transformation into macrophages. It also inhibits the proliferation and migration of vascular smooth muscle cells, inhibits the formation of foam cells, and reduces the plaque instability by directly acting on the arterial wall [11]. PPARα inhibits gene transcription related to inflammatory response and slows down plaque formation by downregulating the expression of inflammatory factors [12]. PPARα inhibits thrombin-induced synthesis of endothelin-1 by activating protein-1-mediated signaling pathways and improves vascular function [13]. Clinical experiments have found significantly reduced levels of plasma interleukin-6 (IL-6), interferon-α (IFN-α), and C-reactive protein (CRP) after taking the PPARα agonist (fibrate) in patients with coronary heart disease confirmed by angiography [14]. Our previous research confirmed that PPARα promotes the repair of endothelial cell injury by upregulating CCL2 expression in human umbilical vein endothelial cells [15]. Some research reported that Tongxin-luo protects diabetic hearts against ischemia/reperfusion injury by activating Angptl4-mediated restoration of endothelial cells [16]. PPARα also plays a role in the induction of p22 and p47phox subunits of the cytosolic Cu, Zn-SOD (SOD1) and attenuates the iron hematoxylin solution (Beyotime, China) for 5 min, and washed with water, dyed with Masson's blue solution before washing with water, dyed with Ponceau magenta dyeing solution for 5–10 min, and immersed in tap water for 10 min to remove the excess staining solution. Then, the sections were stained with eosin solution (Beyotime, China) for 2 min, dehydrated with gradient ethanol (75%, 95%, and 100%), made transparent with xylene for 2 min, dehydrated with gradient ethanol, made transparent with xylene, dehydrated with gradient ethanol, dehydrated with gradient ethanol, and washed with water. The sections were returned to blue for 3–5 minutes with Masson's blue solution before washing with water, dyed with Ponceau magenta dyeing solution for 5–10 min, stained with aniline blue solution for 1–2 min after washing with weak acid working solution and phosphomolybdic acid solution for 1–2 min, dehydrated with gradient ethanol, made transparent with xylene, covered with neutral balsam after washing with weak acid working solution, and observed under a microscope.

2.2. Hematoxylin and Eosin Staining. Apoe−/− mice were deeply anesthetized by intraperitoneal injections of sodium pentobarbital (80 mg/kg) and with 20 mL of 0.9% saline, followed by 50 mL of 4% paraformaldehyde in cold 0.01 M phosphate-buffered saline (PBS, pH 7.4). After perfusion, the left ventricular outflow tract tissue was carefully removed and postfixed for additional 24 hours in the same fixation solution at 4°C. Paraffin sections of the left ventricular outflow tract tissues of Apoe−/− mice were dewaxed with xylene (Sinopharm, China), hydrated with gradient ethanol (100%, 95%, and 75%) (Sinopharm, China), stained with hematoxylin solution (Beyotime, China) for 5–10 min, and immersed in tap water for 10 min to remove the excess staining solution. Then, the sections were stained with eosin solution (Beyotime, China) for 2 min, dehydrated with gradient ethanol (75%, 95%, and 100%), made transparent with xylene for 5 min, and covered with neutral balsam (Beyotime, China). The tissue sections were observed under a microscope (Olympus, Japan), where the nuclei were stained blue and the cytoplasm was pink or red.

2.3. Masson’s Trichrome Staining. Masson’s trichrome staining is a classical method of staining connective tissue and collagen fibers, where muscle fibers are stained red and collagen fibers are green or blue (Solarbio, China). Briefly, paraffin sections of the left ventricular outflow tract tissues of Apoe−/− mice were dewaxed with xylene, hydrated with gradient ethanol, dyed with the prepared Weigert’s iron hematoxylin staining solution for 5–10 min, differentiated with acidic ethanol differentiation solution for 5–15 s, and washed with water. The sections were returned to blue for 3–5 minutes with Masson’s blue solution before washing with water, dyed with Ponceau magenta dyeing solution for 5–10 min, stained with aniline blue solution for 1–2 min after washing with weak acid working solution and phosphomolybdic acid solution for 1–2 min, dehydrated with gradient ethanol, made transparent with xylene, covered with neutral balsam after washing with weak acid working solution, and observed under a microscope.
2.4. Transmission Electron Microscopy. Apoe<sup>-/-</sup> mice were anesthetized by intraperitoneal injections of sodium pentobarbital (80 mg/kg) and perfused with 20 mL of 0.9% saline, followed by 50 mL of 3% glutaraldehyde. Plaque tissues of the aorta were taken under a dissecting microscope and cut to 1 mm<sup>2</sup>. The excised aortic plaque tissues were immersed in 3% glutaraldehyde for 3 days. Aortic plaque tissues were postfixed in 2% osmium tetroxide for 2 h, stained with 1% uranyl acetate for 60 min before rinsing in water, and dehydrated in graded concentrations of ethanol. Subsequently, the tissues were embedded in 812 embedding resin (VWR-Bie and Berntsen A/S, Herlev, Denmark) and polymerized at 60°C for 24 hours. Sections (70 nm thick) were collected on copper grids coated with 2% parlodion and stained with Reynold’s lead citrate. Imaging was conducted with a JEM-1011 transmission electron microscope (JEOL, Japan).

2.5. Beta Galactosidase Staining. The dewaxing and rehydration process of the paraffin section of left ventricular outflow tract tissue of Apoe<sup>-/-</sup> mice was performed as previously described. The cultured human umbilical vein endothelial cells (HUVECs) were fixed with 4% paraformaldehyde before washing in PBS for beta galactosidase (β-gal) (Beyotime, China) staining. Briefly, the prepared β-gal staining solutions were added to tissue sections or cell culture dishes and incubated at 37°C incubator overnight. Tissue sections were covered with 75% glycerol, and the tissues and cells were observed directly under the microscope.

2.6. Immunofluorescence Double Labeling Staining. Dewaxed and hydrated paraffin sections of the left ventricular outflow tract tissue of Apoe<sup>-/-</sup> mice were boiled with sodium citrate at 100°C for 30 min to repair antigens. The sections were blocked with a blocking solution (Beyotime, China) at room temperature for 30 min. They were exposed to the diluted primary antibody solution containing a primary antibody (CD31/p16 or CD31/GDF11). A CD31 rabbit monoclonal antibody (mAb) (1:200) was purchased from Cell Signaling Technology (CST, USA), while p16 mouse mAb (1:200) and GDF11 mouse mAb (1:100) were purchased from Abcam. The tissue sections were incubated with primary antibodies at 4°C for 24 h and washed with PBS for three times after discarding the primary antibody. Subsequently, the sections were incubated with a secondary antibody (goat anti-rabbit IgG Alexa Fluor 546 and/or goat anti-mouse IgG Alexa Fluor 488, 1:500, Thermo Fisher Scientific, USA) at 37°C for 1 h and washed with PBS three times before covering with 75% glycerol containing 1% DAPI (Beyotime, China). Finally, the tissue sections were observed under a fluorescence microscope (Olympus, Japan).

2.7. Cell Culture. EA.hy926 cells (Cell Bank, Shanghai Institute for Biological Science, Shanghai, China) and primary HUVECs were separately cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, USA) or endothelial cell growth medium-2 (EGM-2, Lonza, USA) at 37°C in a humidified atmosphere of 95% air and 5% CO₂, EA.hy926 cells were used for RNA and protein extraction, luciferase assay, and electrophoretic mobility shift assay (EMSA), while HUVECs were used for the β-gal staining assay, ki67 staining assay, terminal deoxyribonucleotide transferase-mediated dUTP-digoxigenin end labeling (TUNEL) staining assay, and angiogenesis assay. Cells treated with PBS were a control group, while cells treated with 200 μg/mL of oxidized low-density lipoprotein (ox-LDL) (YuanYe Biotechnology, China) for 24 h were a model group. PPARα and GDF11 overexpressed or knocked down lentivirus was purchased from Shanghai Novobio Biotechnology Co., Ltd. The virus titer was 1 × 10<sup>8</sup>TU/mL. Cells were seeded in cell culture dishes or plates, and the virus infection was realized when the density of cells reached more than 90%. According to the number of infected cells, viruses and virus infection enhancement solution HitransG A were added. The cells were cultured at 37°C for 24 h before the culture media were refreshed, according to the number of green fluorescent protein-expressing cells. The rate of cell infection was examined 72 h after the infection. The cell infection rate greater than 90% could be used for functional experiments. Cell groups with overexpressed PPARα or GDF11 were labeled as PPARα ov or GDF11 ov, respectively; cells with interfered PPARα or GDF11 were labeled as PPARα RNAi or GDF11 RNAi, respectively. PPARα and GDF11 ov groups or RNAi groups were all accompanied by model condition. GDF11 RNAi and PPARα agonists were only added to ox-LDL treatment cells.

2.8. Real-Time PCR Assay. Total RNA was extracted from aortic tissue of Apoe<sup>-/-</sup> mice or the cultured cells. The SYBR Green Real-Time PCR Master Mix Kit (Toyobo, Japan) was used for all polymerase chain reactions (PCR). Two microliters of cDNA, 0.4 μmol forward and reverse primers, 1 μL SYBR Green Real-Time PCR Master Mix, and appropriate amount of distilled water made up the 20 μL reaction system for target gene amplification. The cycle steps of real-time PCR included the following: 95°C for 60 s and 40 PCR cycles (95°C denaturing for 5 s and 60°C annealing and extension for 30 s). In the amplification curve and dissolution curve, a region where the fluorescence increased exponentially was observed for analyzing the authenticity of the acquired data. The comparative threshold cycle (ΔC<sub>t</sub>) method was used to quantify target mRNAs, and GAPDH was used as an internal reference gene. The primers used for reaction were as follows: p16 (sense 5′-GCAGGAGGTTCCTGGTACGTG-3′ and antisense 5′-TGTTACAGGAAA GCCAGAGCG-3′), p66 (sense 5′-AAGTACAACCAGACT CCGAAGATG-3′ and antisense 5′-AAAAAGAAGGACACAGGGTAGTC-3′), junD (sense 5′-GGCGGGATTGACCCAAGGG-3′ and antisense 5′-AGCCGGTGTCCTGCATCG-3′), TNFa (sense 5′-TTGGAACTTTGGGAGGAGC TAGG-3′ and antisense 5′-CATAAGGCCTTGCTG TTCC-3′), IL-1β (sense 5′-CTCCTCTTTTCAGGGCCA-3′ and antisense 5′-GGGTTTCTCGATCATAGC TG-3′), IL-6 (sense 5′-AGACAGGCACCTACCTCT C-3′ and antisense 5′-AGTGCCCTTTGCTGTTTTC-3′),
C-X-C motif ligand 10 (CXCL10) (sense 5′-CCAAGTGGGTGGCCGTACTTATTTTCT-3′ and antisense 5′-GGCTGGCGAGAGGCATATTCAAA-3′), plasminogen activator inhibitor-1 (PAI-1) (sense 5'-TCTGGGGAAAGGGTTCATTACC-3′ and antisense 5′-GAGGGAGAGAAC-3′), matrix metalloproteinase-3 (MMP3) (sense 5′-GGCTGGAAACAAGCTTGGCG-3′ and antisense 5′-GGATCTCGTTCATCATCGTCA-3′), and GAPDH (sense 5′-ACCCAGAAAGCTGTGGAATGGG-3′ and antisense 5′-TCAGCCTACAGGATGACCTTG-3′). All primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.

2.9. Western Blot Assay. Total protein was extracted from the aortic tissue of Apoe−/− mice or the cultured cells. The BCA protein assay kit (Beyotime, China) was used for total protein concentration determination. Namely, 30 µg of total proteins was subjected to SDS-PAGE, and the proteins were transferred to 0.22 µm aperture nitrocellulose filter membranes (PVDF membranes, Millipore, USA). The PVDF membrane was blocked with 2% bovine serum albumin (BSA) for 30 min at room temperature and incubated with the primary antibody at 4°C overnight. It was washed with 0.1 M PBS for three times, followed by incubation with secondary antibodies at room temperature for 2 h after PBS washing. Finally, the ECL chemiluminescence detection kit was used for protein quantification. Primary polyclonal antibodies included anti-p16 (1:1000, CST, USA), anti-p66sHC (1:2000, CST, USA), anti-junD (1:1000, Boster, China), anti-PPARα (1:5000, CST, USA), anti-p66shc (1:2000, CST, USA), anti-p16 (1:1000, CST, USA), anti-p66shc (1:2000, CST, USA), and anti-β-actin (1:5000, CST, USA). Secondary horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse immunoglobulin- (Ig-) G antibodies (1:2000) were purchased from Cell Signaling Technology.

2.10. Luciferase Reporter Assay. EA.hy926 cells seeded into six-well cell culture plates were infected with the lentivirus GDF11 plasmid. Human GDF11 gene promoter reporter gene plasmids include PDS131_psiCHECK-2 blank vector (6273 bp), PDS131_psiCHECK-2-GDF11 wild type (wt, gene synthesis of the GDF11 gene 5′-UTR 195 bp and promoter region 1500 bp and subcloning into the reporter vector), and PDS131_psiCHECK-2-GDF11 mutant (mut, deletion mutation of “AAGGCCCAG” in the promoter region of the wild-type vector GDF11 gene) (Novobio Biotechnology Co. Ltd., Shanghai, China). The dual-luciferase reporter assay kit (Beyotime, China) was used to detect the luciferase activity in each group after 72 h from the transfection. The microplate reader ( Molecular Devices, USA) was used to detect the corresponding value of the fluorescence emitted by the firefly luciferase-inducing substrate (FL). Then, the corresponding value of the fluorescence released by the Renilla luciferase-inducing substrate (RL) was detected. The ratio of the value of FL to RL was measured for each sample as the relative luciferase activity of the reporter gene.

2.11. Electrophoretic Mobility Shift Assay. Total nuclear proteins were extracted from the cultured cells using a cell fraction kit (CST, USA). Namely, 0.5× TBE nondenaturing gel (5.5%) was equipped for protein gel electrophoresis. At first, preelectrophoresis (120 V) was performed for 30 min. Protein and corresponding probe (the probe labeled with biotin) were mixed and placed at room temperature for 20 min. Sample buffer was added to the sample mixture (protein and probe) for electrophoresis (180 V, 60 min). Subsequently, probe-labeled protein was transferred to the PVDF membrane, and the transferred PVDF was crosslinked at 20 cm under the ultraviolet lamp for 20 min. The nylon membrane after crosslinking was blocked with a blocking solution at room temperature for 20 min and was incubated with a streptavidin-HRP conjugate antibody (1:2000) for 30 min. The membrane was equilibrated with the equilibration solution for 5 min. The ECL chemiluminescence detection kit was used to detect the signaling. The probes included PPARα probe (5′-TCACCCCTCCCAATGGC GGCC-3′-biotin), cold probe (5′-TCACCCCTCCCAATGGC GGCC-3′), and mutant probe (5′-TCACCCCTCCCAAC GGCC-3′-biotin), loading samples including negative control (labeled probe only), control (protein only), PPARα probe (protein plus labeled probe), cold probe (protein plus unlabeled probe), and mutant probe (protein plus mutant probe plus unlabeled probe).

2.12. Cell Proliferation Assay. HUVECs treated with ox-LDL or transfected with GDF11 plasmids were fixed with 4% paraformaldehyde twice for 10 min at room temperature. The fixed cells were rinsed with PBS and blocked with a blocking solution containing 5% normal goat serum. A primary ki67 antibody (Beyotime, China) was used for detecting the proliferation of cells. Goat anti-rabbit IgG Alexa Fluor 546 was used to display red marked cells as proliferating HUVECs, while DAPI was used to counterstain the nuclei. The number of ki67-positive cells was counted under a microscope and compared between the groups.

2.13. Angiogenesis Assay. HUVECs treated with ox-LDL or transfected with GDF11 plasmids were seeded into the Matrigel® basement membrane- (BD, USA) coated 96-well plates. HUVECs were incubated for 48 h with EGM-2 culture medium including 20 ng/mL VEGF165 (Lonza, USA). Angiogenesis was observed under an optical microscope, and the number of branch points in each group was used for comparison between groups.

2.14. TUNEL Staining. The TUNEL (Beyotime, China) assay was used to detect apoptotic cells. HUVECs seeded in 24-well plates were fixed with 4% paraformaldehyde. Then, 0.3% Triton X-100 diluted in PBS was added to the cells and incubated for 5 min at room temperature. TUNEL solution was added to the cells and incubated at 37°C for 60 min in the dark. The cells were covered with 75% glycerol and observed under a fluorescence microscope. The number of green fluorescent labeled cells in each group was compared between the groups.

2.15. Statistical Analysis. Statistical analysis was performed using SPSS v. 18.0 software (SPSS Inc., USA). All data were presented as mean ± SD. One-way ANOVA and Tukey’s post
hsc $t$-tests were used to determine the level of statistical significance. $P < 0.05$ was considered to have a statistically significant difference.

3. Results

3.1. PPAR$\alpha$ Inhibits Atherosclerotic Plaque Formation and Vascular Endothelial Injury. PPAR$\alpha$ is widely involved in lipid metabolism. Since the disturbance of lipid metabolism is an important factor leading to the formation of atherosclerotic plaque, PPAR$\alpha$ plays an important role in regulating atherosclerotic plaque formation. The current and our previous research found that PPAR$\alpha$ was involved in the repair of endothelial cell damage. Given that endothelial cell injury is the beginning of AS, we investigated how PPAR$\alpha$ affects the occurrence of AS. First, we showed that PPAR$\alpha$ agonists inhibited atherosclerotic plaque formation (Figure 1(a)) and played a role in promoting plaque stability in the Apoe$^{-/-}$ mouse model (Figure 1(b)). Then, we observed the effect of PPAR$\alpha$ on the aortic endothelial cell damage in Apoe$^{-/-}$ mice by transmission electron microscopy. Namely, the results showed that the endothelial cells in the plaques of the aortic tissue of the Apoe$^{-/-}$ model mice lost their basic cellular structure, and most of them were in the state of apoptosis and denudation. Endothelial cells were even missing in some plaques of the aortic tissue of Apoe$^{-/-}$ model mice. The PPAR$\alpha$ agonist ensured that the surface of the aortic plaque was covered with intact endothelial cells, and it inhibited endothelial cell apoptosis and necrosis. Intact endothelial cells inhibited monocyte adhesion and reduced the secretion of inflammatory factors, thereby preventing the formation of AS plaques. PPAR$\alpha$ antagonists played the opposite role and promoted endothelial cell apoptosis, necrosis, and denudation (Figure 1(c)). We speculated that PPAR$\alpha$ inhibited atherosclerotic plaque formation by protecting vascular endothelial cells.

3.2. PPAR$\alpha$ Inhibits Aging of Endothelial Cells in the Apoe$^{-/-}$ Mouse Model. Aging caused by continued cell damage is the main pathological factor of AS. Therefore, $\beta$-gal staining
was used to observe the aging cells in Apoe⁻/⁻ mice plaques. We detected a large number of senescent cells in the left ventricular outflow plaques of Apoe⁻/⁻ mice in each group. The senescent cells were distributed in different areas of the plaque, including the endothelial cell distribution area, foam cell distribution area, and smooth muscle cell distribution area, depending on the size of the atherosclerotic plaque and the pathological stage. The number of senescent cells in the atherosclerotic plaque also varied among the groups. Specifically, Apoe⁻/⁻ model mice had a large number of senescent cells in the atherosclerotic plaque, but the number of senescent cells decreased after administration of the PPARα agonist (Figure 2(a)). To further clarify whether PPARα can inhibit vascular endothelial cell aging in Apoe⁻/⁻ mice, the left ventricular outflow tract tissue sections of Apoe⁻/⁻ mice were used to observe the aging of vascular endothelial cells. Endothelial cells were marked with CD31 (green), senescent cells were marked with p16 (red), and senescent endothelial cells (merged) were yellow. Although the results showed a large number of aging endothelial cells in the atherosclerotic plaque of Apoe⁻/⁻ control mice, the basic morphology of senescent endothelial cells was still retained and the denudation of endothelial cells was not observed. However, besides the large number of senescent cells, intact vascular endothelial cells were not detected in Apoe⁻/⁻ model mice, indicating that the senescent endothelial cells at the AS plaques of Apoe⁻/⁻ model mice were denudated. The PPARα agonist inhibited the denudation and maintained the integrity of aging endothelial cells in Apoe⁻/⁻ model mice (Figure 2(b)). The results indicated that PPARα participated in the development of AS by inhibiting the aging of vascular endothelial cells.

3.3 Expression of Aging-Related Proteins in the Apoe⁻/⁻ Mouse Aorta. Based on the existence of a large number of senescent cells in the atherosclerotic plaques of the left ventricular outflow tract of Apoe⁻/⁻ mice, we detected the expression of...
aging-related proteins in the aortic tissue of Apoe−/− mice. Real-time PCR showed that the PPARα agonist significantly inhibited the expression of p16 and p66shc and promoted the expression of GDF11 at the mRNA level. In contrast, the PPARα antagonist inhibited the expression of GDF11 at the mRNA level. Western blot showed that the PPARα agonist significantly inhibited the expression of p16 and p66shc and promoted the expression of GDF11 at the protein level. In contrast, the PPARα antagonist inhibited the protein level of JunD and GDF11. Immunofluorescence double labeling staining showed that the PPARα agonist promoted the expression of GDF11, while the PPARα antagonist inhibited the expression of GDF11 in vascular endothelial cells. *P < 0.05, #: vs. model.

Scale bar, 100 μm.
Figure 4: Continued.
GDF11, while the PPARα antagonist inhibited the expression of GDF11 in vascular endothelial cells (Figure 3(c)). Therefore, we speculated that PPARα might inhibit the aging of vascular endothelial cells in Apoe<sup>−/−</sup> model mice by promoting the expression of GDF11.

3.4. PPARα Targeting GDF11 Participates in the Regulation of Vascular Endothelial Cell Senescence and AS. To further verify whether PPARα inhibits vascular endothelial cell senescence by promoting GDF11 expression, HUVECs were used in vitro to observe the effect of PPARα and GDF11 on endothelial cell function. First, PPARα was overexpressed or interfered within HUVECs to observe their aging. The results showed that overexpression of PPARα significantly inhibited cell senescence, while interference with PPARα significantly promoted cell senescence (Figure 4(a)). Real-time PCR and western blot were used to detect the effect of PPARα on the expression of senescence-related proteins in cultured vascular endothelial cells. The damage of ox-LDL to the cultured endothelial cells led to the upregulation of p16 and the downregulation of GDF11 at the mRNA level. PPARα significantly inhibited the upregulation of p16 and the downregulation of GDF11 caused by ox-LDL (Figure 4(b)). At the protein level, p16 and p66shc were both upregulated whereas GDF11 and junD were both downregulated in the cultured vascular endothelial cells subjected to ox-LDL. The expression of p66shc and JunD was not consistent with that of mRNA, which might suggest that PPARα does not directly regulate the expression of p66shc and JunD (Figure 4(c)). On the basis of the results regarding the effect of PPARα on the expression of aging-related proteins in vivo and in vitro, we further verified whether PPARα directly targets GDF11 to regulate vascular endothelial cell senescence using EMSA and luciferase assays. The EMSA results showed that PPARα bound to the labeled target probe, and partially to the mutant probe, indicating that PPARα could bind to the GDF11 target sequence and participate in the regulation of downstream gene transcription. (c) Double-luciferase reporter gene experiment results indicated that PPARα could bind to the GDF11-specific sequence. 

![Figure 4](image-url)

**Figure 4:** PPARα targets GDF11 expression. (a) β-gal staining showed that overexpression of PPARα significantly inhibited cell senescence. (b) Real-time PCR showed that PPARα significantly inhibited the upregulation of p16 and the downregulation of GDF11 caused by ox-LDL exposure of cultured vascular endothelial cells (200 μg/mL). (c) Western blot showed that the PPARα agonist significantly promoted GDF11 expression and inhibited p16 and p66shc expression. (d) EMSA results showed that PPARα bound to the labeled target probe, and partially to the mutant probe, indicating that PPARα could bind to the GDF11 target sequence and participate in the regulation of downstream gene transcription. (e) Double-luciferase reporter gene experiment results indicated that PPARα could bind to the GDF11-specific sequence. *: $P < 0.05$, **: $P < 0.01$, #: vs. control, #: vs. model.
Figure 5: Continued.
We speculated that the role of GDF11 in inhibiting GDF11 avoided apoptosis caused by ox-LDL endothelial cells, but vascular endothelial cells that overexpressed GDF11 expression achieved the function of regulating vascular endothelial cell senescence by targeting GDF11. To further clarify that PPARα agonist enhanced GDF11 expression, while the PPARα agonist enhanced GDF11 expression in the stable GDF11-knockdown HUVECs with or without ox-LDL and PPARα agonist, weak expression of GDF11 was detected (Figure 6(a)). Next, we examined the mRNA level of senescence-related secretory phenotype (SASP). RT-qPCR revealed a stark increment in SASP (including TNFα, IL-1β, IL-6, CXCL10, PAI-1, and MMP3) in HUVECs (with or without GDF11 knockdown) treated with ox-LDL. In the control group, the PPARα agonist partially suppressed the expression of SASP, while in the GDF11 interference group, the PPARα agonist lost the effect of inhibiting the expression of SASP (Figure 6(b)). These data suggested that PPARα is involved in regulating cell senescence by targeting GDF11. To further clarify that PPARα achieves the function of regulating vascular endothelial cell senescence by targeting GDF11, we examined the effects of PPARα on aging, angiogenesis, proliferation, and apoptosis of HUVECs with GDF11 knockdown (Figures 6(c)–6(f)). We showed that when GDF11 expression was inhibited, the ability of PPARα to promote HUVEC proliferation and angiogenesis was significantly reduced, while senescent and apoptotic cells increased significantly in these HUVECs. Based on the above data, we concluded that PPARα inhibits senescence of vascular endothelial cells through upregulating the expression of GDF11 in HUVECs.

4. Discussion

Vascular endothelial cell senescence is closely related to AS, and our previous study found that PPARα is related to the damage and repair of vascular endothelial cells and the occurrence of AS. In our research, we first predicted whether PPARα targeted senescent-related proteins (p16, p21, p66shc, junD, sirt1, and GDF11) using online databases (http://jaspar.genereg.net/). The two best matching proteins were junD and GDF11. Therefore, we tested the expression of aging-related proteins in the aortic tissues of ApoE-/- model mice which were given PPARα agonists and antagonists and found that PPARα agonists did not affect the expression of junD at the mRNA level but greatly promoted the expression of GDF11. Therefore, we profoundly explored whether PPARα affects vascular endothelial cell senescence by regulating GDF11 expression. AS starts with the damage of vascular endothelial cells [9, 22]. Normal endothelial cells have a perfect mechanism of repairing damage, which can prevent endothelial cells from releasing cytokines and chemokines. In contrast, the senescent endothelial cells have a significantly reduced damage repair ability, which manifests in the release of a number of chemokines to promote monocyte adherence, aggregation, and migration to the intimal layer of blood vessels. Monocytes engulf oxidative lipids to form characteristic foam cells and promote the formation of AS plaques [23, 24]. Therefore, the prevention or repair of vascular endothelial cell damage is the primary factor to delay the occurrence of AS. PPARα is a ligand-activated transcription factor of clinical interest as a drug target in various metabolic disorders, which also contributes to the activity of endothelial nitric oxide synthase (eNOS) and regulates vascular tone [12, ...
Figure 6: Continued.
Figure 6: PPARα influence on the function of vascular endothelial cells is achieved by regulating GDF11. (a) Western blot showed GDF11 expression while adding ox-LDL or PPARα agonist to the stable GDF11-knockdown HUVECs. (b) Real-time PCR revealed a stark increment in SASP (including TNFα, IL-1β, IL-6, CXCL10, PAI-1, and MMP3) in HUVECs (with or without GDF11 knockdown) treated with ox-LDL. (c–f) When GDF11 expression was inhibited, the ability of PPARα to promote HUVEC proliferation and angiogenesis was significantly reduced, while senescent and apoptotic cells increased significantly. **, *P < 0.01, ∗ vs. control, # vs. model. Scale bar, 100 μm or 200 μm.
PPARα gene variants appear to be associated with higher plasma lipid levels and increased risk of coronary artery disease [26]. Although PPARα has the function of promoting eNOS synthesis and repairing cell damage, novel PPARα drugs with therapeutic potential for metabolic syndrome and cardiovascular diseases both target the lipid reduction. Some research reported that PPARγ protects against vascular aging [27], but there were few studies on the correlation between PPARα and aging. Our previous RNA sequence research found that PPARα was involved in the regulation of damaged vascular endothelial cell repair [15]. The causes of endothelial cell aging mainly include cell replication aging and stress-induced cell premature senility. In addition to telomere shortening, the genetic factors, DNA damage, and oxidative stress are the causes of cell replication senescence. Stress-induced cell premature senility usually shows an aging phenotype within hours to days; therefore, failure to repair damaged cells in a timely and accurate manner is an important cause of cell aging. We speculated that the role of PPARα in repairing damaged vascular endothelial cells was crucial for preventing senescence and AS.

GDF11 is a member of the TGFβ superfamily with a controversial role in aging processes. The current evidence on GDF11 indicates a potential key role in reversing several pathological processes associated with aging, although the association with age-related AS is still unclear. Of note, it was shown previously that GDF11 is a circulating factor that reverses age-related cardiac hypertrophy [28]. Considering the existence of regenerative capacity of endogenous GDF11 in the peripheral tissues and brain, it will be important to investigate the mechanisms with therapeutic potential for a variety of age-related cardiovascular diseases [29–31]. However, the research of quantification of GDF11 in human aging and cardiovascular disease indicated that individuals with higher GDF11 were more likely to be frail, and higher GDF11 at surgical baseline was associated with rehospitalization and multiple adverse events [32]. It was reported that GDF11 induces loss of cardiac and skeletal muscle mass and function [33]; in contrast, the recent study indicated that exogenous GDF11 protected the heart from acute myocardial ischemia-reperfusion injury and suggested its role in promoting morphological and functional recovery in the early stage of myocardial ischemia-reperfusion injury [34]. Therefore, additional research is required to fully understand the extent of GDF11 influence on age-related changes under physiological and pathophysiological conditions. At present, there have been few studies on the effect of GDF11 on the function of vascular endothelial cells and AS. Using adeno-associated viruses-GDF11 and recombinant GDF11, it was found that GDF11 protects against endothelial injury and reduces atherosclerotic plaque in Apoe−/− model mice. [35] We over-expressed or interfered with GDF11 in primary HUVECs cultured in vitro and found that GDF11 inhibited cell senescence and apoptosis and promoted cell proliferation and angiogenesis. These effects have certain significance for inhibiting the occurrence of AS.

In summary, we demonstrated a likely causal role for PPARα in vascular endothelial cell senescence and occurrence of AS, where PPARα inhibited cell aging and plaque formation by directly targeting GDF11. Pharmacologic stimulation of PPARα alleviated atherosclerotic plaque formation, vascular endothelial cell damage, and senescence, as well as increasing GDF11 expression in Apoe−/− model mice. At the same time, we proved that PPARα directly targeted the aging-related protein GDF11, thereby affecting the aging, proliferation, apoptosis, and angiogenesis of vascular endothelial cells in vitro. Our findings are consistent with the general hypothesis that inhibiting the aging of vascular endothelial cells helps prevent the formation of atherosclerotic plaques. Our work suggests that targeting PPARα or senescent vascular endothelial cells could be a promising avenue for delaying, preventing, alleviating, or treating AS.

5. Conclusions

In conclusion, our results suggested that PPARα inhibited vascular endothelial cell senescence and apoptosis and promoted vascular endothelial cell proliferation and angiogenesis by heightening GDF11 production, thereby delaying the occurrence of AS. We also suggested that vascular endothelial cell senescence was the key driver of AS formation. These novel findings provide a new highly promising strategy for the prevention of vascular endothelial cell senescence and AS.

Data Availability

All data used to support the findings of this study were collected in accordance with the scientific research criteria and are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Chuan Chen and Zhihua Yu were responsible for the study conception and design. Experiments were performed by Fangfang Dou. Beiling Wu and Jiuling Chen analyzed the data. Fangfang Dou and Te Liu wrote the manuscript and revised it critically for important intellectual content. All authors read and approved the manuscript. Fangfang Dou and Beiling Wu contributed equally to this work and should be considered co-first authors.

Acknowledgments

The present study was supported by grants from the Natural Science Foundation of China (program no. 81704129) and from the Shanghai Municipal Health Bureau Youth Fund (ZY (2018-2020)-CCCX-4004).

References

[1] Y. Dong, C. Fernandes, Y. Liu et al., “Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis,” Diabetes & Vascular Disease Research, vol. 14, no. 1, pp. 14–23, 2017.
[2] B. J. Choi, A. Prasad, R. Gulati et al., "Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque," European Heart Journal, vol. 34, no. 27, pp. 2047–2054, 2013.

[3] J. D. Erusalisky and C. Skene, "Mechanisms of endothelial senescence," Experimental Physiology, vol. 94, no. 3, pp. 299–304, 2009.

[4] T. Hayashi, K. Yano, H. Matsui-Hirai, H. Yokoo, Y. Hattori, and A. Iguchi, "Nitric oxide and endothelial cell senescence," Pharmacology & Therapeutics, vol. 120, no. 3, pp. 333–339, 2008.

[5] V. Lubrano and S. Balzan, "LOX-1 and ROS, inseparable factors in the process of endothelial damage," Free Radical Research, vol. 48, no. 8, pp. 841–848, 2014.

[6] J. Papaconstantinou, "The role of signaling pathways of inflammation and oxidative stress in development of senescence and aging phenotypes in cardiovascular disease," Cell, vol. 8, no. 11, p. 1383, 2019.

[7] S. P. Gendron, M. Thériault, S. Proulx, I. Brunette, and P. J. Rochette, "Restoration of mitochondrial integrity, telomere length, and sensitivity to oxidation by in vitro culture of Fuchs endothelial corneal dystrophy cells," Investigative Ophthalmology & Visual Science, vol. 57, no. 14, pp. 5926–5934, 2016.

[8] E. W. Young and C. A. Simmons, "Macro- and microscale fluid flow systems for endothelial cell biology," Lab on a Chip, vol. 10, no. 2, pp. 143–160, 2010.

[9] M. Tesauro, A. Mauriello, V. Novella et al., "Arterial ageing: from endothelial dysfunction to vascular calcification," Journal of Internal Medicine, vol. 281, no. 5, pp. 471–482, 2017.

[10] N. Bougarbe, B. Weyers, S. J. Desmet et al., "Molecular actions of PPARα in lipid metabolism and inflammation," Endocrine Reviews, vol. 39, no. 5, pp. 760–802, 2018.

[11] N. Hennuyer, I. Duplan, C. Paquet et al., "The novel selective PPARα modulator (SPPARMa) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis," Atherosclerosis, vol. 249, pp. 200–208, 2016.

[12] F. Lalloyer, K. Wouters, M. Baron et al., "Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 7, pp. 1573–1579, 2011.

[13] Y. Jeon, Y. Jung, M. C. Kim et al., "Sargahydroquinoic acid inhibits TNFα-induced AP-1 and NF-κB signaling in HaCaT cells through PPARα activation," Biochemical and Biophysical Research Communications, vol. 450, no. 4, pp. 1553–1559, 2014.

[14] T. Jakob, A. J. Nordmann, S. Schandelmaier, I. Ferreira-González, and M. Briel, "Fibrates for primary prevention of cardiovascular disease events," Cochrane Database of Systematic Reviews, vol. 11, CD009753, 2016.

[15] F. Dou, B. Wu, L. Sun et al., "Identification of a novel regulatory pathway for PPARα by RNA-seq characterization of the endothelial cell lipid peroxidative injury transcriptome," Open Biology, vol. 9, no. 12, article 190141, 2019.

[16] K. Qi, X. Li, Y. Geng et al., "Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopeitin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway," PLoS One, vol. 13, no. 6, article e0198403, 2018.

[17] S. Z. Duan, M. G. Usher, and R. M. Mortensen, "PPARs: the vasculature, inflammation and hypertension," Current Opinion in Nephrology and Hypertension, vol. 18, no. 2, pp. 128–133, 2009.

[18] Z. Israeli-Konaraki and P. D. Reaven, "Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications," Cardiology, vol. 103, no. 1, pp. 1–9, 2005.

[19] L. Han, W. J. Shen, S. Bittner, F. B. Kraemer, and S. Azhar, "PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α", Part I: PPAR-α. Future Cardiol, vol. 13, no. 3, pp. 259–278, 2017.

[20] M. Sairyo, T. Kobayashi, D. Masuda et al., "A novel selective PPARα modulator (SPPARMa), K-877 (pemafibrate), attenuates postprandial hyperglycemia in mice," Journal of Atherosclerosis and Thrombosis, vol. 25, no. 2, pp. 142–152, 2018.

[21] H. E. Xu, T. B. Stanley, V. G. Montana et al., "Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR-α", Nature, vol. 415, no. 6873, pp. 813–817, 2002.

[22] J. J. E. Koopman and R. S. Kuipers, "From arterial ageing to cardiovascular disease," Lancet, vol. 389, no. 10080, pp. 1676–1678, 2017.

[23] J. C. Wang and M. Bennett, "Aging and atherosclerotic mechanisms, functional consequences, and potential therapeutics for cellular senescence," Circulation Research, vol. 111, no. 2, pp. 245–259, 2012.

[24] D. H. Thijssen, S. E. Carter, and D. J. Green, "Arterial structure and function in vascular ageing: are you as old as your arteries?", The Journal of Physiology, vol. 594, no. 8, pp. 2275–2284, 2016.

[25] P. Gervois and R. M. Mansouri, "PPARα as a therapeutic target in inflammation-associated diseases," Expert Opinion on Therapeutic Targets, vol. 16, no. 11, pp. 1113–1125, 2012.

[26] W. Fan, C. Shen, M. Wu, Z. Y. Zhou, and Z. R. Guo, "Association and interaction of PPARα, δ, and γ gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population," Genetic Testing and Molecular Biomarkers, vol. 19, no. 7, pp. 379–386, 2015.

[27] M. L. Modrick, D. A. Kinzenbaw, Y. Chu, C. D. Sigmund, and F. M. Faraci, "Peroxisome proliferator-activated receptor-γ protects against vascular aging," American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 302, no. 10, pp. R1184–R1190, 2012.

[28] F. S. Loffredo, M. L. Steinhauser, S. M. Jay et al., "Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy," Cell, vol. 153, no. 4, pp. 828–839, 2013.

[29] L. Rochette, M. Zeller, Y. Cottin, and C. Vergely, "Growth and differentiation factor 11 (GDF11): functions in the regulation of erythropoiesis and cardiac regeneration," Pharmacology & Therapeutics, vol. 156, pp. 26–33, 2015.

[30] G. Q. du, Z. B. Shao, J. Wu et al., "Targeted myocardial delivery of GDF11 gene rejuvenates the aged mouse heart and enhances myocardial regeneration after ischemia-reperfusion injury," Basic Research in Cardiology, vol. 112, no. 1, p. 7, 2017.

[31] L. Rochette, A. Meloux, E. Rigal et al., "Regenerative capacity of endogenous factor: growth differentiation factor 11; a new approach of the management of age-related cardiovascular events," International Journal of Molecular Sciences, vol. 19, no. 12, p. 3998, 2018.

[32] M. J. Schafer, E. J. Atkinson, P. M. Vanderboom et al., "Quantification of GDF11 and myostatin in human aging and
cardiovascular disease,” *Cell Metabolism*, vol. 23, no. 6, pp. 1207–1215, 2016.

[33] T. A. Zimmers, Y. Jiang, M. Wang et al., “Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting,” *Basic Research in Cardiology*, vol. 112, no. 4, p. 48, 2017.

[34] H. H. Su, J. M. Liao, Y. H. Wang et al., “Exogenous GDF11 attenuates non-canonical TGF-β signaling to protect the heart from acute myocardial ischemia-reperfusion injury,” *Basic Research in Cardiology*, vol. 114, no. 3, p. 20, 2019.

[35] W. Mei, G. Xiang, Y. Li et al., “GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in apolipoprotein E-null mice,” *Molecular Therapy*, vol. 24, no. 11, pp. 1926–1938, 2016.